Linezolid-Resistant Mycobacterium Tuberculosis: A highly concerning situation for the Tuberculosis Eradication Programme

<bold>Title:</bold> Linezolid-resistant Mycobacterium Tuberculosis: a highly concerning situation for the tuberculosis eradication program. <bold>Objective:</bold> · Identification of drug sensitivity in Multi Drug Resistant tuberculosis culture isolates <bold>Method:</bold> The National TB Elimination Programme (NTEP) database is connected to the study site. Nikshay Portal will be used for the patient's sputum smear examination and DST report collection. Only MDR Confirmatory isolates were used in this experiment. Only DST for levofloxacin (Lfx), Moxifloxacin (Mfx-1.0), pyrazinamide (Z), and linezolid (Lzd) was performed here. <bold>Result:</bold> The results reveal that the prevalence of Mfx- 644 (37%), Pyrazinamide- 462 (26.98%), and LNZ-resistant isolates is 19 (1%) among 1712 MDR-TB isolates and drug susceptibility testing (DST) against LNZ is useful in the management of complicated and drug-resistant cases. However, further studies could identify other possible genetic mechanism of resistance in TB. <bold>Conclusion:</bold> The data indicate that 1% of MDR-TB isolates are LNZ-resistant, drug susceptibility testing (DST) against LNZ is useful in the management of complex and drug-resistant infections. Nonetheless, Genetic investigation is required for resistance mechanisms related to tuberculosis. The use of LZD in the treatment of drug-resistant tuberculosis has improved treatment outcomes; yet, the development of resistance to this medication calls for the surveillance of clinical isolates of M. tuberculosis for LZD sensitivity.